Cisplatin Induces Down Regulation of BCL2 in T47D Breast Cancer Cell Line - RIIP - Réseau International des Instituts Pasteur Accéder directement au contenu
Article Dans Une Revue Advanced Studies in Biology Année : 2012

Cisplatin Induces Down Regulation of BCL2 in T47D Breast Cancer Cell Line

Résumé

Over expression of the anti-apoptotic protein BCL2 has been associated with several malignancies. BCL2 is a prognostic marker in breast cancer. The BCL2 protein is a highly conserved member of the BCL2 family and constitutes an important regulator of apoptosis. Apoptosis is the main response of cells to chemotherapeutic agents including cisplatin. In this study, T47D cells were treated with various concentrations of cisplatin (0, 3.125, 6.25, 12.5, 25, 50, 100μM) for 24h. Then, cell viability was assessed using MTT assay and IC50 was determined. RNA was extracted and cDNA was synthesized. In the present study, BCL2 was chosen as target and TBP was chosen as internal control gene, respectively. Specific primers were designed by primer express software v.3.0. target /control gene expression ratios were calculated by 2 -ΔΔCt formula. The Real-time PCR results showed that BCL2 gene expressions were decreased. The results showed that cisplatin exerted a dose-dependent inhibitory effect on the viability, via down regulation of BCL2 gene, in T47D cells.

Domaines

Autre [q-bio.OT]
Fichier principal
Vignette du fichier
Cisplatin.pdf (254.87 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Loading...

Dates et versions

pasteur-00768870 , version 1 (26-12-2012)

Identifiants

  • HAL Id : pasteur-00768870 , version 1

Citer

Mohammad Javad Mokhtari, Azim Akbarzadeh, Mehrdad Hashemi, Gholamreza Javadi, Reza Mahdian, et al.. Cisplatin Induces Down Regulation of BCL2 in T47D Breast Cancer Cell Line. Advanced Studies in Biology, 2012, 4 (1), pp.19-25. ⟨pasteur-00768870⟩

Collections

RIIP RIIP_IRAN
396 Consultations
1408 Téléchargements

Partager

Gmail Facebook X LinkedIn More